News

Already approved for metastatic melanoma, Merck & Co’s Keytruda has shown promising activity for difficult-to-treat triple-negative breast cancer.

GlaxoSmithKline’s shingles vaccine HZ/su has smashed efficacy goals in a late-stage trial slashing the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo.

Just days after announcing its mega-deal with Cubist Merck & Co is on the acquisition trial again with its sights set on private Swiss cancer biotech OncoEthix.

Roche’s pictilisib, a pan inhibitor of the PI3 kinase enzyme has failed to improve outcomes when combined with fulvestrant in patients with estrogen receptor positive (ER+) metastatic breast cancer in a mid-stage trial.

US researchers have found 53 existing approved drugs that may keep the Ebola virus from entering human cells, a key step in the process of infection.

Women suffering from advanced relapsed BRCA-mutated ovarian cancer could gain access to a new treatment option after European regulators waved through AstraZeneca’s Lynparza (olaparib).

German drug major Bayer has lost its long-running battle to get India’s first-ever compulsory licence – for its liver and kidney cancer drug Nexavar (sorafenib tosylate) – overturned.

Scientific and political changes will make adaptive pathways the preferred approach to making new treatments available to patients, according to a leading group of scientists.

As expected, Boehringer Ingelheim’s bloodthinner Pradaxa (dabigatran) is now routinely available on the National Health Service for treating and preventing potentially fatal blood clots in the lungs and legs.

Europe’s innovative and generics drugmakers have come together to urge the continent’s lawmakers to adopt an integrated life sciences strategy.

Patients with a rare type of cancer called gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have gained access to a new treatment option following US approval of Ipsen’s Somatuline Depot (lanreotide) injection.

Germany’s decision to withdraw 80 generic drugs from the market cannot apply to 18 of the products because of the legal challenges brought by their manufacturers against the ban, the national drug regulator has said.

Johnson & Johnson group Janssen Biotech has bought itself access to Halozyme Therapeutics’ drug delivery enhancing system in a deal valued at up to $581 million.

Pfizer has kicked off a Phase II study assessing its investigational compound PF-06252616 in Duchenne muscular dystrophy (DMD).

The rumour mill is running wild with renewed reports of a possible marriage between Dublin, Ireland-based Shire and US group NPS Pharmaceuticals.